Key Stats for Regeneron Stock
- Current Price: $634.62
- Target Price (Mid): ~$1,030
- Street Target (Mean): ~$833
- Potential Total Return (Mid): ~62%
- Annualized IRR (Mid): ~11% / year
- Q1 2026 Earnings Reaction: +3.02% (4/29/26)
- Max Drawdown: -22.48% (5/18/26)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
The Damage, and the Question It Raises
Regeneron Pharmaceuticals (REGN) entered May at $716. It is now at $634.62, and the reason is specific. A Phase 3 trial testing fianlimab, a LAG-3 inhibitor (a drug that blocks an immune checkpoint which suppresses the body’s T-cell attack on tumors), combined with cemiplimab in first-line metastatic melanoma did not reach statistical significance for progression-free survival versus pembrolizumab monotherapy, despite showing a numeric 5.1-month improvement in median PFS for the high-dose combination.
Citi downgraded REGN from Buy to Neutral and cut its price target to $700 from $900, citing the absence of incremental positive catalysts. Jefferies analyst Akash Tewari removed fianlimab from his model entirely while keeping a Buy rating, calling the miss unsurprising. RBC Capital trimmed its target to $707, flagging the failure alongside a broader pattern of recent pipeline setbacks. REGN’s max drawdown reached 22.48% on 5/18/26, its deepest in the current period, per TIKR.
At $634.62, the stock trades at an NTM P/E of 13.09x per TIKR. The question the selloff raises is whether the core commercial business, which never depended on fianlimab for its mid-case earnings trajectory, is being discounted alongside a pipeline that did disappoint.
What Fianlimab Was Actually Worth
Ryan Crowe, Regeneron’s Senior Vice President of Investor Relations, placed the global metastatic melanoma market at $2 billion to $3 billion at the Bank of America Global Healthcare Conference on May 12, three days before the miss was public. RBC had estimated peak probability-adjusted sales of $1.6 billion to $1.8 billion for fianlimab in this indication, all of which is now removed from near-term models.
A head-to-head trial against Bristol Myers Squibb’s Opdualag is ongoing, and Regeneron’s investor relations materials confirmed a second interim analysis for the adjuvant melanoma program in H2 2026. Crowe himself called the adjuvant setting “much higher risk” at the May 12 conference, before the Phase 3 result made that framing look accurate.
The near-term verdict is straightforward: fianlimab revenue is off the table. The remaining question is how much of the core business the market is now mispricing alongside it.
See historical and forward estimates for Regeneron stock (It’s free!) >>>
The Core Business Is Intact
Strip out fianlimab, and what remains is durable. DUPIXENT (dupilumab), co-commercialized with Sanofi, is running at roughly a $20 billion annual global revenue rate across nine U.S. indications, per McCourt’s disclosure at the May 12 conference. Penetration in atopic dermatitis, its largest single indication, remains only in the high-teens percentage of patients who could benefit. The commercial runway is not close to exhausted.
COPD is where physician interest is sharpest right now. DUPIXENT is the first biologic ever approved for COPD, and Crowe made the competitive picture clear at the conference: the only other biologic in the COPD market has never demonstrated lung function improvement, while DUPIXENT showed approximately 80 mL improvement in FEV1 (forced expiratory volume in one second, the clinical gold standard for lung function measurement). Patients are reducing or eliminating supplemental oxygen dependence a qualitative shift preceding broader prescription growth.
On the eye franchise, EYLEA HD (aflibercept 8 mg, a next-generation retinal injection) now makes up approximately 50% of the combined EYLEA franchise in net sales. Per Regeneron’s Q1 2026 earnings release, EYLEA HD U.S. net sales grew 52% to $468 million. The expanded FDA label dosing intervals up to 20 weeks, plus the new retinal vein occlusion indication, support adoption. A prefilled syringe remains pending FDA review, and McCourt noted that roughly 95% of EYLEA 2mg volume runs through prefilled form, making that clearance a meaningful commercial step.
TIKR’s segment data shows the transition’s trajectory clearly: EYLEA 2mg net sales fell from $4,767.10 million in 2024A to $2,747.80 million in 2025A, while EYLEA HD grew from $1,201.10 million to $1,636.90 million over the same period. The math still requires EYLEA HD to accelerate, and the label expansions and pending prefilled syringe are the levers.
The Catalyst Wall Street Is Underweighting
The most consequential financial event for REGN over the next twelve months is not pipeline-related. The Sanofi development balance, a profit-sharing obligation from DUPIXENT’s early development years that has compressed Regeneron’s collaboration revenue, is expected to clear in Q3 2026, per Regeneron’s Q1 2026 earnings release. Once it does, Regeneron begins receiving its full share of DUPIXENT profits.
This is a contractual accounting event, not a pipeline bet. TIKR’s Actuals and Forward Estimates data show normalized EPS at $44.31 in 2025A, rising to $46.25 in 2026E, then stepping up to $53.77 in 2027E, a 16% jump in a single year driven primarily by this profit-share clearing. Free cash flow grew from $3,664.60 million in 2024A to $4,080.50 million in 2025A and is forecast by TIKR at around $5.2 billion in 2026E, pushing FCF margins from 28.4% toward 33%.
Crowe also clarified the scope of Regeneron’s Most Favored Nation (MFN) pricing agreement with the U.S. government at the May 12 conference. The deal covers only products wholly owned by Regeneron in the U.S. EYLEA and EYLEA HD are included. DUPIXENT co-commercialized with Sanofi is not. For investors discounting REGN on fears of near-term government price caps on DUPIXENT, that distinction removes a meaningful part of the risk premium baked into the current price.
On valuation multiples, REGN trades at an NTM EV/EBITDA of 6.50x against AbbVie at 12.96x and Amgen at 10.48x per TIKR’s Competitors data, a discount of more than 50% to both peers. The company carries a net cash position of $15,833.59 million per TIKR’s capital structure data, and 21 of 29 analysts rate it Buy or Outperform with a mean Street target of approximately $833, implying around 31% upside from the current price.
The risks are real. EYLEA 2mg biosimilar pressure is intensifying, with additional entrants expected in H2 2026. R&D expense guidance of $5.9 billion to $6.1 billion for 2026 weighs on near-term GAAP earnings. And consecutive pipeline misses raise legitimate questions about oncology execution. Per Regeneron’s Q1 2026 earnings release, DUPIXENT global net sales grew 33% to $4.9 billion in Q1 2026 alone, and the core engine is not stalling. Trading it at a 50%-plus EV/EBITDA discount to peers requires believing the engine breaks. The data does not yet support that.
See how Regeneron performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $634.62
- Target Price (Mid): ~$1,030
- Potential Total Return: ~62%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for Regeneron stock (It’s free!) >>>
The mid-case uses a revenue CAGR of around 6% through 2035E and a net income margin of 37%, conservatively below REGN’s 5-year historical average of 43.1% and in line with its 10-year average of 34.2%. The two revenue drivers are DUPIXENT’s continued global expansion and EYLEA HD’s displacement of EYLEA 2mg as the retinal standard of care.
The high case (~$1,500) requires COPD to scale into a second blockbuster DUPIXENT indication and fianlimab’s adjuvant interim to surprise positively in H2 2026, the higher-risk path. The low case (~$970) prices in accelerated EYLEA 2mg erosion and a DUPIXENT pricing renegotiation before 2030. The primary risk to the mid-case is the pace of the EYLEA transition: TIKR’s segment data already shows HD accelerating, but the 2mg decline is steep, and the prefilled syringe approval is still pending.
Conclusion
The fianlimab miss is real, and the pipeline credibility hit is real. But at 6.50x NTM EV/EBITDA with $15.8 billion in net cash, the stock is priced for a deterioration of the core business that the financials do not support. The single number that will confirm or break this view is Sanofi’s collaboration revenue in Q3 2026 results, expected late October 2026. A step-change increase, not a modest lift, is what “on track” looks like. That is the line to watch.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Regeneron?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Regeneron, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Regeneron alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Regeneron on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
